Company intelligence / Profile preview

AI Optics

New York, New York, United States

Ownership: Private
Development stage: Other

Overview

AI Optics has FDA 510(k) clearance for its Sentinel Camera, a portable handheld retinal imaging system that enables high-quality, point-of-care retinal screening. The AI-based diagnostic software (Sentinel Pro) is under development and not yet FDA-cleared. No published clinical trial results for the investigational AI screening software as of now.

Therapeutic areas: Ophthalmology
Modalities: DeviceAI-based diagnostic software
Industry: Medical Imaging

Partnerships

NYU Langone Health

Beyond the preview

Go deeper on AI Optics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AI Optics.

Explore the full profile